GSK came into this Q3 2026 print with the shares under pressure, down about 6% over three months and closing at £18.14 on 29 October. The stock has carried a value label, trading on a trailing P/E of 16.7x against richer pharma peers, yet the fresh quarter tells a more nuanced story. Revenue reached £8.9b and basic earnings per share landed at about £0.38. The market reaction focuses on the short term. The real tension sits in how that earnings power lines up against a business still digesting a £3.8b one off loss and a thinner 13% net margin.
Love the value tag on GSK but concerned about a thinner 13% net margin and that £3.8b one off loss still hanging over the story? Scan the list of solid balance sheet and fundamentals stocks (10 results) for companies that combine resilient earnings power with sturdier financial profiles.
Q3 2026 GSK Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): £8,887m vs. £8,547m (up about 4.0%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): £1,543m vs. £2,013m (down about 23.3%)
- Basic EPS (Q3 2026 vs Q3 2025): £0.3849 vs. £0.4990 (down about 22.9%)
- Products in Phase III Pipeline (Q3 2026 vs Q3 2025): 19 vs. 16 (pipeline expanded by 3 late stage projects)
GSK is pouring cash into Phase III while holding guidance firm. Ask Charlie what GSK’s late‑stage R&D splurge really signals.
Evaluating GSK’s Specialty Pivot Against Q3 Delivery
Supporters argue that GSK’s pipeline shift will convert into higher quality earnings over time.
"The main requirement is continued execution on GSK’s data and AI enabled R&D and cost reallocation program, so the expanded late stage pipeline turns into durable cash flows."
Q3 shows that thesis partially landing. Specialty medicines grew 15%, with HIV, respiratory and early oncology launches like Jideytro and Exdensur contributing, while Phase III assets increased to 19 from 16 as R&D spend rose 22%. At the same time, core EPS rose only 1% and reported profit fell because of £328m of restructuring charges, so the cash flow upgrade that bullish investors want remains more pipeline than P&L reality.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.
GSK Bear Case: General Medicines Drag vs Specialty Progress
Bearish investors argue that GSK’s weaker legacy drugs and discontinued projects will blunt the impact of its newer portfolio.
"Bearish analysts expect GSK to see its General Medicines pressures, discontinued assets and product-specific issues prevent the newer portfolio from fully offsetting the drag on growth and margins."
Q3 delivery partly fits that worry. Specialty medicines grew 15% and Phase III projects increased to 19, yet core EPS rose only 1% while reported profit fell after £328m of restructuring charges and a thinner 13% net margin. Vaccines declined 2% and overall operating profit dropped 16%. In the near term, the earnings bridge from specialty strength to group level improvement still appears incomplete.
Hunt Quiet Disconnects In Plain Sight
GSK just reported a mixed quarter that challenges simple value labels and headline reactions. The real opportunity could sit in stocks where fundamentals and pricing have started to drift apart.
- Company 1 - 47% below our estimate - use new leisure centres and a recent platform acquisition to roll out more sites using data led pricing tools.
- Company 2 - 34% below our estimate - build a subscription led appliance and electronics model that leans on recommerce and reverse logistics to reduce cost to serve.
- Company 3 - 31% below our estimate - extend an IT infrastructure and services platform into AI heavy and international projects through targeted acquisitions and system upgrades.
That is three of the list. See the full list of 10 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com